Pain in oxaliplatin-induced neuropathy - Sensitisation in the peripheral and central nociceptive system

被引:76
作者
Binder, Andreas [1 ,2 ]
Stengel, Maike [1 ,2 ]
Maag, Rainer [1 ,2 ]
Wasner, Gunnar [1 ,2 ]
Schoch, Robert [3 ]
Moosig, Frank [3 ]
Schommer, Bernhard [4 ]
Baron, Ralf [1 ,2 ]
机构
[1] Div Neurol Pain Res & Therapy, D-24105 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Neurol, D-24105 Kiel, Germany
[3] Univ Hosp Schleswig Holstein, Dept Med 2, D-24116 Kiel, Germany
[4] Univ Teaching Hosp Rendsburg, Dept Med, D-24768 Rendsburg, Germany
关键词
oxaliplatin; quantitative sensory testing (QST); neuropathy; cold; pain; sensitisation;
D O I
10.1016/j.ejca.2007.07.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aimed to determine the somatosensory characteristics and pain types in patients with acute oxaliplatin-induced neuropathy and to relate this profile to the hereby detected underlying pathophysiological mechanisms. Patients and methods: Sixteen patients treated with oxaliplatin for cancer were characterised with neurological assessment and a standardised and validated set for quantitative sensory testing (QST). Patients were allocated to two groups depending on the presence or absence of pain symptoms of acute neuropathy. Results: Comparison with normative data revealed in patients with pain symptoms a characteristic somatosensory profile of cold and mechanical hyperalgesia. Group-to-group analysis revealed additional heat hyperalgesia and warm hypoesthesia. Conclusion: Pain symptoms of acute oxaliplatin-induced neuropathy are related to signs of sensitisation within the peripheral (cold and heat hyperalgesia) and central nervous nociceptive system (mechanical hyperalgesia). This strengthens the rationale for treatment with anticonvulsants and antidepressants and fosters research on ion channel and receptor related mechanisms. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2658 / 2663
页数:6
相关论文
共 30 条
[1]   The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons [J].
Adelsberger, H ;
Quasthoff, S ;
Grosskreutz, J ;
Lepier, A ;
Eckel, F ;
Lersch, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :25-32
[2]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[3]   Mechanisms of Disease: neuropathic pain - a clinical perspective [J].
Baron, R .
NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (02) :95-106
[4]   Oxaliplatin-related side effects: Characteristics and management [J].
Cassidy, J ;
Misset, JL .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20
[5]   Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat [J].
Cavaletti, G ;
Tredici, G ;
Petruccioli, MG ;
Dondè, E ;
Tredici, P ;
Marmiroli, P ;
Minoia, C ;
Ronchi, A ;
Bayssas, M ;
Etienne, GG .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) :2457-2463
[6]   Oxaliplatin-associated neuropathy: A review [J].
Cersosimo, RJ .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) :128-135
[7]   An SCN9A channelopathy causes congenital inability to experience pain [J].
Cox, James J. ;
Reimann, Frank ;
Nicholas, Adeline K. ;
Thornton, Gemma ;
Roberts, Emma ;
Springell, Kelly ;
Karbani, Gulshan ;
Jafri, Hussain ;
Mannan, Jovaria ;
Raashid, Yasmin ;
Al-Gazali, Lihadh ;
Hamamy, Henan ;
Valente, Enza Maria ;
Gorman, Shaun ;
Williams, Richard ;
McHale, Duncan P. ;
Wood, John N. ;
Gribble, Fiona M. ;
Woods, C. Geoffrey .
NATURE, 2006, 444 (7121) :894-898
[8]   Oxaliplatin - A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies [J].
Culy, CR ;
Clemett, D ;
Wiseman, LR .
DRUGS, 2000, 60 (04) :895-924
[9]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]   Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy [J].
Durand, JP ;
Alexandre, J ;
Guillevin, L ;
Goldwasser, F .
ANTI-CANCER DRUGS, 2005, 16 (05) :587-591